• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Herpes zoster not significantly associated with subsequent increased incidence of cancer [CMAJ]

bys25qthea
September 24, 2012
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image : CC/Ian Porter

Key findings:

1.     Herpes zoster was not found to be a risk factor for subsequent cancer, though there were significantly higher incidences of melanomas and bone/soft-tissue malignancies

2.     There is insufficient evidence to warrant investigating for occult malignancy or closer surveillance for new onset cancer in individuals with herpes zoster

Primer: Herpes zoster is a viral illness (often referred to as shingles) that presents with painful, bullous skin rash often along a dermatome. It is caused by reactivation of the varicella zoster virus, and is commonly seen in immunocompromised individuals. There is limited and conflicting evidence exploring the link between herpes zoster and the risk of developing subsequent cancer, with some studies suggesting herpes zoster is a risk factor for developing malignancy and others suggesting the opposite is true. Furthermore, much of the existing evidence explores the association in western countries, and this may be of limited applicability to Asian populations.

For further reading regarding the link between herpes zoster and developing malignancy, please see the following studies:

RELATED REPORTS

Optogenetic therapy may partially restore vision in retinitis pigmentosa

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

1.     Ragozzino MW, Melton LJ III, Kurland LT, et al. Risk of cancer after herpes zoster: A population-based study. NEJM 1982;307:393-397.
2.     Buntinx F, Wachana R, Bartholomeeusen S, et al. Is herpes zoster a marker for occult or subsequent malignancy? Br J Gen Pract 2005;55:102-107.
 

This [retrospective cohort] study: Published recently in CMAJ, a population-based, retrospective cohort study sought to explore whether there was increased incidence of cancer after herpes zoster in the Taiwanese population. The final analysis involved 35,871 patients with newly diagnosed herpes zoster, and 895 cases of cancer were subsequently identified. There was no increased risk of cancer compared with the general population, though there was increased risk of certain malignancies, including melanoma (standardized incidence ratio 2.03; 95% CI 1.01-3.63) and bone/soft-tissue cancers (2.03; 95% CI 1.11-3.41).

In sum: This study demonstrated that there was no increased risk of cancer amongst patients subsequent to herpes zoster. There were higher incidences of melanoma and bone/soft-tissue malignancies after episodes of herpes zoster. This study contrasts with 2 recent publications suggesting that herpes zoster is a risk factor for developing malignancy, though these differences may be due to differences in the ethnicity of the study populations.

The strength of this study is that it was conducted using a large national, population-based registry of data. The study suffers from limitations often encountered in observational studies, including the fact that follow-up was limited to 9 years, while longer follow-up may be necessary to detect newly onset malignancies.

While the evidence regarding herpes zoster as a risk factor for subsequent malignancy is still quite limited, there is no strong evidence to support closer surveillance for cancer after episodes of shingles. Moreover, there is insufficient evidence to warrant screening for occult malignancy in patients who develop herpes zoster.

Click to read in CMAJ

By AC

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCALIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Previous Post

Multifaceted programs to improve handover at discharge from hospital significantly improves hospital use and continuity of care [Ann Intern Med.]

Next Post

Surgical versus conventional therapy for weight loss treatment of obstructive sleep apnea [JAMA]

RelatedReports

A woman using a red light therapy device while seated, surrounded by workout equipment and papers, suggesting engagement in wellness practices.
Chronic Disease

Optogenetic therapy may partially restore vision in retinitis pigmentosa

October 23, 2026
A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
A man walking along a path surrounded by healthy food options, sporting shoes, a heart illustration, and urban scenery, indicating lifestyle changes for cardiovascular health.
Cardiology

Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status

October 22, 2026
An illustration depicting a bowl of vegetables, a smartphone, and a representation of the gut microbiome inside the human intestinal tract.
Chronic Disease

Children with autism spectrum disorder may have reduced fecal microbial diversity

October 21, 2026
Next Post

Surgical versus conventional therapy for weight loss treatment of obstructive sleep apnea [JAMA]

Sugar-free beverages significantly reduce weight gain in children

Thalidomide shows efficacy as a potential anti-tussive for idiopathic pulmonary fibrosis

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Optogenetic therapy may partially restore vision in retinitis pigmentosa
  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
  • Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.